Sanner achieves over EUR 85 million sales record

Optimistic outlook despite Corona crisis

With Sanner BioBase, the company launched the first effervescent tablet packaging made of bio-based material.

Germany-based Sanner, an international manufacturer of pharmaceutical primary packaging and medical technology products, has completed a successful business year 2019, with a total turnover of just over EUR 85 million (approximately Rs 720 crore), company mentioned this in a press statement.

Due to investments in new products and existing sites, Sanner is optimistic about the future despite the Corona crisis. With a group turnover of more than EUR 85 million (approximately Rs 720 crore), Sanner has set a new company record. The development in Europe was stable; slight increases were achieved in China. The company recorded an above-average growth of 25% in the US and even more than 30% in India.

According to the company, the demand is particularly strong for products from the “Engineered Product Solutions” segment. Sanner offers diagnostic solutions such as rapid tests and pulmonary applications such as inhalers and customized primary packaging.

“We will continue to expand our business in the coming years. This includes innovations in the existing Sanner product portfolio as well as investments in internal developments,” says Johannis Willem van Vliet, managing director of the Sanner Group. “We are already successfully working on integrating electronics into injection molded parts. A further focus is on smart packaging and medical device development. We are thus expanding our competence and strengthening our value proposition – high volumes in plastics processing at the highest quality.”

New products and market segments

At the beginning of this year, the company launched Sanner BioBase, the first effervescent tablet packaging made of bio-based material. The tablet tube is recyclable and increases resource efficiency. Higher H20 barrier properties extend the tablets’ shelf life, an essential argument for customers and consumers. In terms of handling, Sanner BioBase offers consumers a high-quality feel and appearance. The tube can be printed or provided with an IML label.

With its range of medical cannabis packaging, the company serves another market segment – and has already developed a first solution with the child-resistant tablet and capsule container TabTec CR. It features Sanner’s patented ‘Press and Flip’ opening mechanism, making it difficult for children to open, but easy for adults to open and reclose. The integrated pouring opening allows individual capsules or tablets to be removed easily and hygienically. Due to its slim shape, the container fits in any shirt or trouser pocket, while the innovative design stands out from other products at the point of sale.

Positive outlook despite Corona crisis

At Sanner, work continues despite the Covid-19 pandemic. The company has even increased its production capacity in Bensheim, Germany, to meet the increased demand, such as for effervescent tablet packaging and medical devices such as inhalers or parts for rapid tests. Three new machines for the production of desiccant closures were already put into operation for this purpose. In China, the plant was ramped up again at the end of February after several weeks of closure and is now running at full speed, with the construction of the second production plant in concrete planning.

Sanner is also continuing to invest in the Bensheim headquarters’ infrastructure, for example, by implementing a new manufacturing execution system. “We expect an increased demand for our products in Europe, the US and Asia – despite or even because of the Corona crisis,” says van Vliet. “Accordingly, we are expecting sales to grow further this year.”


Please enter your comment!
Please enter your name here